131970-21-3

Basic information

• Product Name: ISRADIPINE
• Synonyms: (+)-4-(Benzofurazan-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 3-isopropyl 5-methyl ester
• CAS NO: 131970-21-3
• Molecular Weight: 0
• Mol File: 131970-21-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ISRADIPINE(CAS DataBase Reference)
• NIST Chemistry Reference: ISRADIPINE(131970-21-3)
• EPA Substance Registry System: ISRADIPINE(131970-21-3)

Safety Data

• Hazardous Substances Data: 131970-21-3(Hazardous Substances Data)

Upstream product

• 104785-90-2 2-acetyl-3-benzofurazan-4-yl-acrylic acid methyl ester 
• 40100-28-5 isopropyl 3-aminocrotonate 
• 75695-93-1 isradipine 

Related news

Optimization & design of ISRADIPINE (cas 131970-21-3) loaded solid lipid nanobioparticles using rutin by Taguchi methodology07/27/2019

Our research objective was to optimize and design nano-biosystem of Isradipine (IDP) via novel bioenhancer (Rutin) loaded solid-lipid nanobioparticles (ANbp) using Taguchi design (TgD) methodology. Firstly, preliminary screening of solid lipid nanoparticles (SLNps) formulation core factors (A, B...detailed

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

AN IMPROVED PROCESS FOR THE MANUFACTURE OF ISRADIPINE.

The present invention relates to an improved method for the manufacture of Isradipine, 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester. which, involves reacting 2,1,3-benzoxadiazole-4-carboxaldehyde with methyl acetoacetate in the presence of acetic acid and piperidine in diisopropyl ether. To obtain the product 2-acetyl-3-benzofurazan-4-yl-acrylic acid methyl ester which is then reacted with isopropyl-?-aminocrotonate in ethanol at 25 to 35°C to obtain the product.